Momelotinib Dosage
Medically reviewed by Drugs.com. Last updated on Nov 7, 2023.
Applies to the following strengths: 200 mg; 150 mg; 100 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Myelofibrosis
200 mg orally once a day
Comment:
- Treatment should be discontinued in patients unable to tolerate 100 mg once daily.
Use: For the treatment of intermediate or high-risk myelofibrosis (MF), including primary or secondary MF (post-polycythemia vera and post-essential thrombocythemia) in patients with anemia
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended
Severe liver dysfunction (Child-Pugh C):
- Starting dose: 150 mg orally once a day
Hepatoxicity (ALT and/or AST greater than 5 times the upper limit of normal [5 x ULN] [or greater than 5 x baseline, if baseline is abnormal] and/or total bilirubin greater than 2 x ULN [or greater than 2 x baseline, if baseline is abnormal]):
- Treatment should be interrupted until AST and ALT are 2 x ULN or less or at baseline (if baseline greater than 2 x ULN) and total bilirubin is 1.5 x ULN or less or at baseline (if baseline greater than 1.5 x ULN).
- Treatment should be restarted at a daily dose of 50 mg below the last given dose; therapy may be reinitiated at 100 mg if previously dosed at 100 mg.
- If reoccurrence of ALT or AST elevations is greater than 5 x ULN, this drug should be permanently discontinued.
Dose Adjustments
Thrombocytopenia:
- Daily dose should be reduced by 50 mg from the last given dose:
- If the baseline platelet count is 100 x 10(9)/L or greater, then decreases to 20 to less than 50 x 10(9)/L
- Treatment should be interrupted until platelets recover to 50 x 10(9)/L, then treatment should be restarted at a daily dose of 50 mg below the last given dose. Therapy may be reinitiated at 100 mg if previously dosed at 100 mg:
- If the baseline platelet count is 100 x 10(9)/L or greater, then decreases to less than 20 x 10(9)/L
- If the baseline platelet count is 50 to less than 100 x 10(9)/L, then decreases to less than 20 x 10(9)/L
- Treatment should be interrupted until platelets recover to baseline, then treatment should be restarted at a daily dose of 50 mg below the last given dose. Therapy may be reinitiated at 100 mg if previously dosed at 100 mg:
- If baseline platelet count is less than 50 x 10(9)/L, then decreases to less than 20 x 10(9)/L
Neutropenia (absolute neutrophil count [ANC] is less than 0.5 x 10[9]/L):
- Treatment should be interrupted until ANC is 0.75 x 10(9)/L or greater, then treatment should be restarted at a daily dose of 50 mg below the last given dose. Therapy may be reinitiated at 100 mg if previously dosed at 100 mg.
Other nonhematologic adverse reactions (grade 3 or higher):
- Treatment should be interrupted until the toxicity resolves to grade 1 or lower (or baseline).
- Treatment should be restarted at a daily dose of 50 mg below the last given dose. Therapy may be reinitiated at 100 mg if previously dosed at 100 mg.
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult the WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- May be administered with or without food
- Swallow whole; do not cut, crush, or chew tablets.
- If a dose is missed, the next scheduled dose should be taken the following day.
Storage requirements:
- Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F).
- Keep in original bottle to protect from moisture.
- Dispense to patients in original bottle only; replace the cap securely after each opening.
- Do not discard desiccant.
Monitoring:
- Hematologic: CBC with platelets (prior to and during therapy)
- Hepatic: Liver function (prior to and every 6 months during treatment); hepatitis B serologies in patients with hepatitis B virus infection (prior to and during therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Patient Information).
- This drug can increase the risk of infections; report signs and symptoms of infection to your health care provider.
- Report any bleeding to your health care provider as this drug can cause abnormal platelet and white blood counts.
- Major cardiovascular events have been reported; current and past smokers and patients at risk for cardiac events should report all signs and symptoms.
- New cancers have been reported in some people taking other medications in the same class as this drug.
- Notify your health care provider if any signs/symptoms of a DVT or pulmonary embolism develop.
- Patients of childbearing potential should use highly effective contraception during therapy and for 1 week after the last dose.
- Notify your prescriber of a known/suspected pregnancy.
- Do not breastfeed during treatment and for at least 1 week after the last dose.
More about momelotinib
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.